UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 6.

Pagani, O; Klingbiel, D; Ruhstaller, T; Nolè, F; Eppenberger, S; Oehlschlegel, C; Bernhard, J; Brauchli, P; Hess, D; Mamot, C; Munzone, E; Pestalozzi, B; Rabaglio, M; Aebi, S; Ribi, K; Rochlitz, C; Rothgiesser, K; Thürlimann, B; Moos, R von; Zaman, K; Goldhirsch, A; Swiss Group for Clinical Cancer Research (SAKK) (2017). Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99. Annals of Oncology, 28(2):305-312.

Nissen, M J; Ciurea, A; Bernhard, J; Tamborrini, G; Mueller, R; Weiss, B; Toniolo, M; Exer, P; Finckh, A (2016). The effect of comedication with a conventional synthetic disease-modifying antirheumatic drug on drug retention and clinical effectiveness of anti-tumor necrosis factor therapy in patients with axial spondyloarthritis. Arthritis and Rheumatology, 68(9):2141-2150.

Ghadjar, P; Hyoz, S; Bernhard, J; Zwahlen, D; Holscher, T; Gut, P; Guckenberger, M; Hildebrandt, G; Muller, A; Plasswilm, J; Papachristofilou, A; Stalder, L; Biaggi-Rudolf, C; Sumila, M; Kranzbuhler, H; Najafi, Y; Ost, P; Azinwi, N; Reuter, C; Bodis, S; Kaouthar, K; Wust, P; Thalmann, G; Aebersold, D (2015). Acute toxicity and quality of life after dose-intensified salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: first results of the randomized trial SAKK 09/10. Journal of Clinical Oncology, 33(35):4158-4166.

Ribi, K; Bernhard, J; Schuller, J C; Weder, W; Bodis, S; Jörger, M; Betticher, D; Schmid, R A; Stupp, R; Ris, H B; Stahel, R A (2008). Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes. Lung Cancer, 61(3):398-404.

Bernhard, J; Dietrich, D; Scheithauer, W; Gerber, D; Bodoky, G; Ruhstaller, T; Glimelius, B; Bajetta, E; Schüller, J; Saletti, P; Bauer, J; Figer, A; Pestalozzi, B C; Köhne, C H; Mingrone, W; Stemmer, S M; Tàmas, K; Kornek, G V; Koeberle, D; Herrmann, R (2008). Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial - SAKK 44/00-CECOG/PAN.1.3.001. Journal of Clinical Oncology, 26(22):3695-3701.

Münger-Beyeler, C; Bernhard, J; Rufibach, K; Morant, R; Schmid, H P (2008). Quality of analgesic treatment in patients with advanced prostate cancer: do we do a better job now? The Swiss Group for Clinical Cancer Research (SAKK) experience. Supportive Care in Cancer, 16(5):461-467.

This list was generated on Tue Jul 25 05:08:24 2017 CEST.